Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer mutations from the BCAC, CIMBA, and ENIGMA consortia

Amanda B Spurdle1, Fergus J Couch2, Michael T Parsons3, Lesley McGuffog3, Daniel Barrowdale2, Manjeet K Bolla3, Qin Wang3,4, Sue Healey1, Rita Katharina Schmutzler5, Barbara Wappenschmidt5, Kerstin Rhiem5, Eric Hahnen5, Christoph Engel6, Alfons Meindl7, Nina Ditsch8, Norbert Arnold9, Hansjoerg Plendl10,11, Dieter Niederacher12, Christian Sutter13, Shan Wang-Gohrke14, Doris Steinemann15, Sabine Preisler-Adams16, Karin Kast17, Raymond Varon-Mateeva18, Steve Ellis9, Debra Frost3, Radka Platтя5, Jo Perkins3, D Gareth Evans19, Louise Izatt20, Ros Eeles21, Julian Adlard22, Rosemarie Davidson23, Trevor Cole24, Giulietta Scuvera25, Siranoush Manoukian25, Bernardo Bonanni26, Frederique Mariette27,28, Stefano Fortuzzi27,28, Alessandra Viel29, Barbara Pasini30,31, Laura Papi3, Liliana Varesco33, Rosemary Balleine34, Katherine L Nathanson35, Susan M Domchek35, Kenneth Offit36, Anna Jakubowska37, Noralane Lindor38, Mads Thomassen39, Uffe Birk Jensen40, Johanna Rantanäki41, Åke Borg42, Irene L Andrilis43,44, Alexander Miron45, Thomas VO Hansen46, Trinidad Caldes47, Susan L Neuhausen48, Amanda E Toland49, Heli Nevanlinna50, Marco Montagnä11, Judy Garber62, Andrew K Godwin53, Ana Osorio54,55, Rachel E Factor56, Mary B Terry57, Timothy R Rebbeck58, Beth Y Karlan59, Melissa Southey59, Muhammad Usman Rashid60,61, Nadine Tung62, Paul DP Pharoad63, Fiona M Blows64, Allison M Dunning64, Elena Provenzano65, Per Hall65, Kamila Czene66, Marjanka K Schmidt66, Annegien Broeks66, Sten Cornelissen66, Senno Verhoef66, Peter A Fasching67,68, Matthias W Beckmann68, Arif B Ekici69, Dennis J Slamon70,71, Stig E Bojesen71,72,73, Børge G Nordestgaard71,72,73, Sune F Nielsen71,72, Henrik Flyger74, Jenny Chang-Claude75, Dieter Flesch-Janys76, Anja Rudolph75, Petra Seibold75, Kristiina Aittomäki77, Taru A Muranen60, Päivi Heikkilä64, Carl Blomqvist80, Jonine Figueroa80, Stephen J Chanock80, Louise Brinton80, Jolanta Lissowska81, Janet E Olson82, Vernon S Pankratz82, Esther M John83,84, Alice S Whittemore84, Dee W West85,86, Ute Hamann87, Diana Torres88, Hans Ulrich Ulmer86, Thomas Rüdiger87, Peter Devilee88, Robert AEM Tollenaa89, Caroline Seynaeve90, Christi J Van Asperen91, Diana M Eccles93, William J Tapper92, Lorraine Durcan92, Louise Jones93, Julian Pett94, Isabel dos-Santos-Silva94, Olivia Fletcher95, Nichola Johnson95, Miriam Dwek96, Ruth Swann96, Anita L Bane97,98, Gord Glendron99, Anna M Mulligan100,101, Graham G Giles102,103, Roger L Milne102,103, Laura Baglietto102,103, Catriona McLean104, Jane Carpenter105, Christine Clarke106, Rodney Scott107,108, Hiltrud Brauch109,110, Thomas Brüning111, Yon-Dschun Ko112, Angela Cox113, Simon S Cross114, Malcolm WR Reed115, Jan Lubinski116, Katarzyna Jaworska-Bieniek117, Katarzyna Durda117, Jacek Gronwald117, Thilo Dörk115, Natalia Bogdanova116, Tjouong-Won Park-Simon116, Peter Hillemanns116, Christopher A Haiman117, Brian E Henderson117, Fredrick Schumacher117, Loic Le Marchand118, Barbara Burwinkel119,120, Frederik Marme119,121, Harald Surovy119,120, Rongxi Yang119,120, Hoda Anton-Culver122, Argyrios Zigos122, Maartje J Hooning123, J Margriet Collée124, John WM Martens123, Madeleine MA Nilsson-Linthorst125,126

* Correspondence: Amanda.Spurdle@qimrberghofer.edu.au
1Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, QLD 4006, Australia
Full list of author information is available at the end of the article

© 2014 Spurdle et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The distribution of histopathological features of invasive breast tumors in BRCA1 or BRCA2 germline mutation carriers differs from that of individuals with no known mutation. Histopathological features thus have utility for mutation prediction, including statistical modeling to assess pathogenicity of BRCA1 or BRCA2 variants of uncertain clinical significance. We analyzed large pathology datasets accrued by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC) to reassess histopathological predictors of BRCA1 and BRCA2 mutation status, and provide robust likelihood ratio (LR) estimates for statistical modeling.

Methods: Selection criteria for study/center inclusion were estrogen receptor (ER) status or grade data available for invasive breast cancer diagnosed younger than 70 years. The dataset included 4,477 BRCA1 mutation carriers, 2,565 BRCA2 mutation carriers, and 47,565 BCAC breast cancer cases. Country-stratified estimates of the likelihood of mutation status by histopathological markers were derived using a Mantel-Haenszel approach.

Results: ER-positive phenotype negatively predicted BRCA1 mutation status, irrespective of grade (LRs from 0.08 to 0.90). ER-negative grade 3 histopathology was more predictive of positive BRCA1 mutation status in women 50 years or older (LR = 4.13 (3.70 to 4.62)) versus younger than 50 years (LR = 3.16 (2.96 to 3.37)). For BRCA2, ER-positive grade 3 phenotype modestly predicted positive mutation status irrespective of age (LR = 1.7-fold), whereas ER-negative grade 3 features modestly predicted positive mutation status at 50 years or older (LR = 1.54 (1.27 to 1.88)). Triple-negative tumor status was highly predictive of BRCA1 mutation status for women younger than 50 years (LR = 3.73 (3.43 to 4.05)) and 50 years or older (LR = 4.41 (3.86 to 5.04)), and modestly predictive of positive BRCA2 mutation status in women 50 years or older (LR = 1.79 (1.42 to 2.24)).

Conclusions: These results refine likelihood-ratio estimates for predicting BRCA1 and BRCA2 mutation status by using commonly measured histopathological features. Age at diagnosis is an important variable for most analyses, and grade is more informative than ER status for BRCA2 mutation carrier prediction. The estimates will improve BRCA1 and BRCA2 variant classification and inform patient mutation testing and clinical management.

Introduction
It is well established that BRCA1-related breast tumors, as a group, differ from non-BRCA1 tumors in terms of histological phenotype. Tumors of BRCA1 mutation carriers are more likely to be high-grade with medullary subtype features, including greatly increased mitotic count, pushing margins, lymphocytic infiltrate, trabecular growth pattern, and necrosis [1-3]. Consistent with overrepresentation of a basal phenotype, a number of immunohistochemical (IHC) markers have been shown to be of value in assessing BRCA1 tumor phenotype in female patients, including estrogen receptor (ER), progesterone receptor (PR), human Epidermal Growth Factor Receptor 2 (HER2), p53, cytokeratin 5/6 (CK5/6), cytokeratin 14 (CK14), cytokeratin 17 (CK17), and epidermal growth factor receptor (EGFR) [4-8]. In addition, several studies reported that reduced expression of CK8/18 can discriminate the basal tumors of BRCA1 mutation carriers from basal tumors of noncarriers [9,10], whereas loss of phosphatase and tensin homolog (PTEN), together with triple-negative (TN; ER-, PR-, HER2-) status, was reported to improve the sensitivity of BRCA1 mutation prediction in a study of Asian breast cancer patients [11]. The introduction of PTEN to BRCA1 mutation-prediction algorithms is supported by single-cell analyses of temporal somatic events in BRCA1 breast tumor tissue, which revealed that loss of PTEN is an early event in the development of BRCA1 basal-like tumors, whereas TP53 mutations occur first in most luminal BRCA1 tumors [12].

The breast tumor phenotype of female BRCA2 female mutation carriers is less distinctive than that of BRCA1 mutation carriers [1,13,14]. Nevertheless, reports based on IHC or expression array analysis have
shown that BRCA2 breast tumors are predominantly of the luminal B subtype [13,15], and are more likely than non-BRCA2 tumors to be ER positive and high grade, with reduced tubule formation and continuous pushing margins [2,13].

A number of these histopathological features have been incorporated into prediction models or have been proposed as selection criteria for prioritizing testing of breast cancer patients for BRCA1 and BRCA2 mutations [11,16-24]. These findings have also served as the basis for including independently predictive tumor histopathological features as a component of the multifactorial likelihood model for clinical classification of BRCA1/2 variants of uncertain significance [25]. The current iteration of the model includes likelihood ratio (LR) estimates of pathogenicity for combined ER and grade or combined ER, CK5/6, and CK14 status, for analysis of BRCA1 variants, and tubule formation for BRCA2 [26-29]. However, these LR estimates were derived from analyses of relatively small datasets including a maximum of 600 mutation carriers and 288 noncarriers [4,6], and have not been directly validated.

We conducted analyses of large pathology datasets accrued by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC) to reassess previously reported histopathological predictors of BRCA1 and BRCA2 mutation status. The results provide more-refined LR estimates for downstream multifactorial likelihood analysis and for prediction of BRCA1 and BRCA2 mutation status.

Methods

Access to data and ethics approvals

ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) is a research consortium aimed to improve methods to assess the clinical significance in breast cancer susceptibility genes [30]. Considerable overlap in membership exists between ENIGMA, CIMBA, and BCAC. As a collaboration between the three consortia, investigators in ENIGMA accessed CIMBA and BCAC datasets for approved pathology-related analyses relevant to the purposes of ENIGMA. The collection of clinical, pathology, and genetic data by CIMBA and BCAC has been previously approved for ongoing research studies by the local ethics committee relevant to each of the participating CIMBA and BCAC studies, and all participants provided informed consent to the relevant participating CIMBA and BCAC sites for such ongoing studies.

Research analyses specific to this study were carried out using only de-identified data, with approval from the Human Research Ethics Committee of the QIMR Berghofer Medical Research Institute, and the Institutional Review Board of the University of Utah.

Sample sets

CIMBA

The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA; [31]) is a consortium established to conduct large-scale research studies of carriers of germline BRCA1 or BRCA2 pathogenic mutations [32]. Specifically, carriers of variants of uncertain significance are ineligible for entry into CIMBA. The major focus is discovery and validation of genetic factors that modify risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers, with consideration of risk stratified by tumor histologic features. Contributing centers provide information relevant to analyses, including year of birth, age at diagnosis of breast and/or ovarian cancer, cancer behavior (invasive, in situ), basic histology, and other pathology measures for breast and ovarian tumors from study participants. Pathology information is extracted mainly from pathology reports, although a small subset of contributing centers have conducted centralized pathology review and/or supplemented clinical IHC results with research testing of tumor material (for example, 5% of ER pathology results were centrally reviewed) [33]. All CIMBA centers with ER and grade data available in the CIMBA database that were from countries with pathology data available from population (presumed noncarrier) reference cases in BCAC (see later) were included in the analyses. Variables included were as follows: gene mutated, mutation nomenclature (and mutation type, for example, truncating, missense, and so on), date of birth, age and date of diagnosis of breast cancer(s), breast cancer behavior, ER status, PR status, HER2 status, Cytokeratin 5 or 5/6 status, and grade. No CK14 IHC results were available. No dual-mutation carriers were found. Only invasive breast cancer cases diagnosed before age 70 years were included, to reduce the likelihood of phenocopy tumors not directly related to mutation status. Samples were included irrespective of ovarian cancer diagnoses. For individuals with two breast cancers (20% of cases), the breast cancer diagnosed closest in time to the entry into the CIMBA cohort was considered preferentially.

BCAC

The Breast Cancer Association Consortium (BCAC [34]) was established to discover and validate genetic factors associated with risk of breast cancer in the general population [35]. BCAC also studies risk factors associated with tumor subtypes and tumor histologic features, and pathology data from participating centers are derived from pathology reports or center-specific research efforts. BCAC pathology data were checked and cleaned
centrally [36]. BCAC centers were selected for inclusion in this analysis based on availability of ER and grade data. Studies in BCAC in which cases were ascertained on the basis of tumor characteristics (for example, the TN consortium) were excluded. Variables provided for analyses were as follows: study type (to identify within-study strata, and/or to define cohorts with familial cases), age at diagnosis of breast cancer(s), breast cancer behavior, ER status, PR status, HER2 status, CK5 or 5/6 status, and grade. No CK14 IHC results were available. The study design was noted as selected (familial and/or age-selected, relevant for 13 studies) or unselected (from population-based or hospital-based design), based on study-ascertainment criteria provided by the principal investigators of individual BCAC sites.

**BRCA1** and **BRCA2** germline mutation testing results were provided by 13 of the 36 BCAC studies (comprising 12% of BCAC individuals overall), nine of which used age/family history selection criteria for case ascertainment (with testing for 4% to 100% of these nine studies). The 345 known mutation carriers (189 **BRCA1**, 156 **BRCA2**) identified in BCAC were excluded. Analysis included subjects known to be noncarriers or untested for **BRCA1/2** mutations, with relevant pathology information for primary invasive breast cancer diagnosis younger than age 70 years. As for CIMBA, for individuals with two breast cancers (only 5% of all BCAC cases younger than age 70 years. As for CIMBA, for individuals with two breast cancers (only 5% of all BCAC cases considered), the breast cancer diagnosed closest in time to the entry into the cohort was included preferentially.

### Statistical analysis

**ER** or grade data were available for 4,477 **BRCA1** mutation carriers, 2,565 **BRCA2** mutation carriers, and 47,565 BCAC breast cancer cases with no known mutation in **BRCA1** or **BRCA2** (presumed noncarriers). The numbers of subjects by country are shown in Table 1. Only countries with ≥200 cases in BCAC and ≥100 carriers in CIMBA were included in analyses to minimize potential bias due to country-specific patterns of pathology assessment. ER-negative, PR-negative, and HER2-negative tumors were categorized as triple-negative (TN). All other combinations of known ER, PR, and HER2 status for a single breast tumor were categorized as “Not TN.” CIMBA and BCAC studies contributing pathology data are noted in Additional file 1: Table S1. Final sample sizes for analyses are reported in footnotes to Tables 2 and 3, and Additional file 1, Tables S2 to S4.

CK5/6 IHC data were available for only 128 **BRCA1** carriers, 78 **BRCA2** carriers and 6,796 BCAC cases with valid data on ER status. Numbers of carriers reduced further after country-matching, and frequencies differed significantly between countries for carriers. Cytokeratin analyses were thus not pursued further.

### Table 1 Subjects in CIMBA and BCAC datasets with breast tumor ER or grade status, by country

| Country   | CIMBA   | BCAC  |
|-----------|---------|-------|
|           | Number **BRCA1** | Number **BRCA2** | Number BCAC noncarriers |
| Australia | 363     | 293   | 2,014 |
| Canada    | 97      | 57    | 927   |
| Denmark   | 201     | 151   | 2,318 |
| Finland   | 55      | 64    | 2,607 |
| Germany   | 982     | 493   | 9,503 |
| Italy     | 547     | 362   | 270   |
| Netherlands | 113      | 32    | 4,181 |
| Poland    | 247     | 0     | 2,527 |
| Spain     | 91      | 102   | 358   |
| Sweden    | 158     | 34    | 5,266 |
| United Kingdom | 642 | 388 | 12,989 |
| USA       | 981     | 589   | 4,605 |

**Total** 4,477 2,565 47,565

Data for primary breast tumor. ER, breast tumor estrogen receptor status; BCAC, Breast Cancer Association Consortium; CIMBA, Consortium for Investigators of Modifiers of **BRCA1** and **BRCA2**. ER status was missing for 548 (12.2%) **BRCA1** carriers, 292 (11.4%) **BRCA2** carriers and 4,942 (10.4%) presumed noncarriers. Histological grade was missing for 890 (19.9%) **BRCA1** carriers, 555 (21.6%) **BRCA2** carriers, and 6,020 (12.7%) presumed noncarriers.

All statistical analyses were performed by using STATA version 12 (StatCorp, College Station, TX, USA). Statistical significance was defined as *P* < 0.05.

We first examined whether family history was related to the predictor variables of interest in the BCAC sample set. Family-history information, defined as first-degree relative with breast cancer, was available for 30,223 individuals (7,547 reporting a family history of breast cancer). Logistic regression analyses were performed to predict ER status, grade 3, or TN status as a function of family history (defined as first-degree relative with breast cancer), adjusting for age at diagnosis and country. No significant effect was observed for family history on any of these histopathologic features, so we did not consider family history further in any analyses.

To identify the most important predictors of mutation status to be used in estimation of the likelihood ratios for classification of variants, we undertook a series of logistic regression analyses. These analyses compared **BRCA1** and **BRCA2** with the BCAC set. A sequential series of models with country and age (younger than 50 years versus 50 years or older) as a starting point and then adding ER, grade, and the ER/grade combination to test for interaction between ER and grade. For those cases who had data on TN status, we examined ER, ER and grade, ER TN, grade TN, and last, models with ER, grade, and TN. Likelihood ratio tests were used to determine the most parsimonious models for each gene.
We then estimated simple likelihood ratios of the form \( L[\text{path}| \text{BRCA}_i]/L[\text{path}| \text{BRCA}_0] \), where \( i = 1, 2 \) to denote tumors from women with germline \( \text{BRCA}_1 \) and \( \text{BRCA}_2 \) mutations, respectively, and \( \text{BRCA}_0 \) to denote cancers from women presumed to be without such mutations. For example, if \( m \) \( \text{BRCA}_1 \) tumors have a given histopathological feature of a total of \( M \) total carriers with measured data on this feature, and \( s \) noncarriers (in this case, from the BCAC set) of a total of \( S \) have the feature of interest, then the LR is estimated by \( (m/M)/(s/S) \). An approximate variance of \( \ln(LR) \) is given by \( \text{Var}[^{\ln(LR)}] = [1/m – 1/M + 1/s – 1/S] \). Thus assuming a normal distribution for \( \ln(LR) \), 95% confidence limits are given by \( \exp[^{\ln(LR)}] ± 1.96\sqrt{\text{Var}[^{\ln(LR)}]} \).

However, to account for potential differences between countries in the distributions of ER status and grade together with large differences in the ratio of carriers to noncarriers, we derived stratified estimates of LR by

| Table 2 Estimated likelihood ratios for predicting \( \text{BRCA}_1 \) or \( \text{BRCA}_2 \) mutation status defined by breast tumor ER and/or grade phenotype* |
|---------------------------------------------------------------|
| **Gene** | **ER status** | **Grade** | **Diagnosis <50 years** | **Diagnosis ≥50-70 years** |
| | | | % Carriers (CIMBA) | % BCAC | LR (95% CI) | % Carriers (CIMBA) | % BCAC | LR (95% CI) |
| **BRCA1** | ER negative | Grade 1 | 0.8 | 1.4 | 0.59 (0.36-0.98) | 0.6 | 1.2 | 0.51 (0.18-1.40) |
| | | Grade 2 | 9.8 | 6.7 | 1.36 (1.18-1.58) | 13.3 | 6.1 | 2.34 (1.88-2.91) |
| | | Grade 3 | 67.1 | 20.8 | 3.16 (2.96-3.37) | 54.5 | 12.8 | 4.13 (3.70-4.62) |
| | ER positive | Grade 1 | 1.0 | 13.7 | 0.08 (0.05-0.12) | 2.3 | 20.6 | 0.11 (0.07-0.18) |
| | | Grade 2 | 7.4 | 36.1 | 0.21 (0.18-0.24) | 14.6 | 43.6 | 0.34 (0.28-0.42) |
| | | Grade 3 | 13.9 | 21.2 | 0.64 (0.57-0.72) | 14.7 | 15.8 | 0.90 (0.73-1.10) |
| | - | Grade 1 | 2.1 | 15.8 | 0.13 (0.10-0.16) | 2.9 | 22.3 | 0.12 (0.08-0.18) |
| | | Grade 2 | 18.1 | 42.8 | 0.38 (0.34-0.42) | 28.7 | 49.1 | 0.57 (0.50-0.65) |
| | | Grade 3 | 79.8 | 41.4 | 1.67 (1.62-1.78) | 68.4 | 28.6 | 2.20 (2.01-2.71) |
| | ER negative | - | 77.5 | 28.8 | 2.60 (2.47-2.73) | 69.4 | 19.9 | 3.31 (3.03-3.61) |
| | ER positive | Grade 1 | 22.5 | 71.2 | 0.32 (0.29-0.34) | 30.6 | 80.1 | 0.37 (0.32-0.42) |
| | | Grade 2 | 18.1 | 42.8 | 0.38 (0.34-0.42) | 28.7 | 49.1 | 0.57 (0.50-0.65) |
| | | Grade 3 | 79.8 | 41.4 | 1.67 (1.62-1.78) | 68.4 | 28.6 | 2.20 (2.01-2.71) |
| | - | Grade 1 | 5.7 | 15.8 | 0.33 (0.26-0.41) | 8.6 | 22.3 | 0.35 (0.27-0.46) |
| | | Grade 2 | 41.8 | 42.8 | 0.88 (0.80-0.95) | 42.0 | 49.1 | 0.81 (0.72-0.92) |
| | | Grade 3 | 52.5 | 41.4 | 1.08 (1.00-1.17) | 49.4 | 28.6 | 1.52 (1.35-1.71) |
| | ER negative | - | 19.2 | 28.8 | 0.66 (0.59-0.74) | 25.1 | 19.9 | 1.18 (1.01-1.38) |
| | ER positive | Grade 1 | 80.8 | 71.2 | 1.15 (1.08-1.22) | 74.9 | 80.1 | 0.90 (0.82-0.98) |
| | | Grade 2 | 18.1 | 42.8 | 0.38 (0.34-0.42) | 28.7 | 49.1 | 0.57 (0.50-0.65) |
| | | Grade 3 | 79.8 | 41.4 | 1.67 (1.62-1.78) | 68.4 | 28.6 | 2.20 (2.01-2.71) |
| | - | Grade 1 | 5.7 | 15.8 | 0.33 (0.26-0.41) | 8.6 | 22.3 | 0.35 (0.27-0.46) |
| | | Grade 2 | 41.8 | 42.8 | 0.88 (0.80-0.95) | 42.0 | 49.1 | 0.81 (0.72-0.92) |
| | | Grade 3 | 52.5 | 41.4 | 1.08 (1.00-1.17) | 49.4 | 28.6 | 1.52 (1.35-1.71) |

*Analyses stratified by country, as detailed in the methods section. LR, Likelihood ratio; ER, breast tumor estrogen-receptor status; BCAC, Breast Cancer Association Consortium. No known mutation status.

ER-Grade analysis included tumor phenotypes from 3,039 \( \text{BRCA1} \) mutation carriers (2,393 < 50 years at diagnosis, 646 ≥ 50 years), 1,718 \( \text{BRCA2} \) mutation carriers (1,217 < 50 years at diagnosis, 501 ≥ 50 years) and 36,603 BCAC cases with no report of positive \( \text{BRCA1}/2 \) mutation status (12,584 < 50 years at diagnosis, 24,019 ≥ 50 years). Grade analysis included tumor phenotypes from 3,587 \( \text{BRCA1} \) mutation carriers (2,825 < 50 years at diagnosis, 762 ≥ 50 years), 2,010 \( \text{BRCA2} \) mutation carriers (1,415 < 50 years at diagnosis, 595 ≥ 50 years) and 41,545 BCAC cases with no report of positive \( \text{BRCA1}/2 \) mutation status (14,678 < 50 years at diagnosis). ER analysis included tumor phenotypes from 3,929 \( \text{BRCA1} \) mutation carriers (3,106 < 50 years at diagnosis, 824 ≥ 50 years), 2,273 \( \text{BRCA2} \) mutation carriers (1,616 < 50 years at diagnosis, 657 ≥ 50 years), and 42,623 BCAC cases with no report of positive \( \text{BRCA1}/2 \) mutation status (14,484 < 50 years at diagnosis, 28,139 ≥ 50 years). Percentages may not total 100 because of rounding error.
Table 3 Estimated likelihood ratios for predicting BRCA1 or BRCA2 mutation status defined by breast tumor triple-negative phenotype

| Gene | Breast tumor phenotype | Diagnosis <50 years | | | Diagnosis ≥50 to 70 years | | |
|------|------------------------|---------------------|---|---|--------------------------|---|---|
|      |                        | % Carriers | % BCAC | LR (95% CI) | % Carriers | % BCAC | LR (95% CI) |
| BRCA1 | Triple-negative        | 67.3 | 17.5 | 3.73 (3.43-4.05) | 57.7 | 12.9 | 4.41 (3.86-5.04) |
|       | Not triple-negative    | 32.7 | 82.5 | 0.40 (0.37-0.44) | 42.3 | 87.1 | 0.49 (0.42-0.56) |
|       |                        | 100% | 100% |               | 100% | 100% |               |
| BRCA2 | Triple-negative        | 13.0 | 17.5 | 0.72 (0.59-0.87) | 23.5 | 12.9 | 1.79 (1.42-2.24) |
|       | Not triple-negative    | 87.0 | 82.5 | 1.06 (0.98-1.15) | 76.5 | 87.1 | 0.88 (0.78-1.00) |
|       |                        | 100% | 100% |               | 100% | 100% |               |

Analyses stratified by country, as described in the Methods section. Analysis included tumor phenotypes from 2,249 BRCA1 mutation carriers (1,788 < 50 years, 461 ≥ 50 years), 1,195 BRCA2 mutation carriers (859 < 50 years, 336 ≥ 50 years) and 19,178 BCAC cases with no report of positive BRCA1/2 mutation status (7,103 < 50 years, 12,075 ≥ 50 years). LR, likelihood ratio. Triple-negative phenotype defined as ER-negative, PR-negative, HER2-negative; not triple-negative; all other combinations, with status measured for all three markers.

using a Mantel-Haenszel approach [37] with approximate 95% confidence intervals calculated according to Greenland and Robins [38]. The country-based strata considered were as follows: Australia, United Kingdom, Germany, USA, and all other countries (with smaller individual sample sizes) pooled. Both stratified and unstratified analyses were conducted for all ages, and by age at diagnosis younger than 50 years versus 50 years or older, when sufficient sample size was available in all groups.

We performed a series of sensitivity analyses to assess how the lack of BRCA1/2 testing in the vast majority of BCAC cases might affect the Likelihood Ratio estimates reported here. First, we determined the probability that each untested BCAC case was a true noncarrier as follows: We calculated the probability, a priori, that each untested BCAC case carried a pathogenic BRCA1 and/ or BRCA2 mutation by using the age-specific relative risks in Antoniou et al. [39] and assuming allele frequencies of pathogenic mutations in each gene of 0.0005. Next we calculated crude LRs for ER-negative and ER-positive tumor status by using only the ~6,000 BCAC cases that tested negative for BRCA1/2, and all the BRCA1 and BRCA2 carriers. Then, assuming the prior calculated in step 1, we used these preliminary ER LRs to calculate the posterior probability that each untested BCAC case had a mutation in BRCA1 or BRCA2 based on their ER status. We calculated the probability that each BCAC case was a true noncarrier for a mutation in either gene, as 1, brca1 probability minus brca2 probability.

Second we reestimated a subset of the LRs by using iterative sampling of BCAC cases from the posterior distribution calculated, as described. We generated a uniform random number for each case, and used this and the posterior probabilities to determine whether each of the untested BCAC cases was a noncarrier, a BRCA1 carrier, or a BRCA2 carrier. We then used these simulated data to reestimate LRs from the whole data set, adjusting for country, as in the initial analysis.

Further, to examine the effects of changes in pathology over time, potential racial/ethnic differences in these features, and possible survival bias, we performed three additional analyses, one estimating overall unstratified ER/grade LRs for diagnosis after 1989; one restricted to white European ancestry cases only; and another of only cases diagnosed within 5 years of recruitment (to avoid possible bias between tumor phenotype and survival).

Results

The principal aim of this study was to reassess histopathological predictors of BRCA1 and BRCA2 mutation status by analysis of datasets considerably larger than those analyzed previously for this purpose, to provide more robust pathology-based likelihood ratios for use in assessing the pathogenicity of BRCA1 or BRCA2 variants. Our main analyses of breast tumor features included up to 3,929 BRCA1 mutation carriers, 2,273 BRCA2 mutation carriers, and 42,623 assumed BRCA1 and BRCA2 mutation-negative breast cancer cases (Tables 2 and 3). This large sample set allowed us to explore ER alone, grade alone, combined ER and grade stratified by age, and ER/PR/HER2 TN status as predictors of BRCA1 and BRCA2 mutation status.

Logistic regression determining best histopathology predictors of mutation status

For BRCA1 carriers, likelihood ratio tests indicated that both ER and grade were strong independent predictors of BRCA1 status compared with the BCAC set (P <10^-20). Marginal evidence suggested that considering grade and ER status jointly improved the fit compared with including them separately in the model (χ² = 6.25, 2 df, P = 0.04). When we considered only cases in which TN status and grade were available, TN significantly added to the model fit, even with ER status in the model; the most
parsimonious model included ER, grade, and TN status, which was significantly better than any model with only two of these included ($\chi^2 = 83.8, 1 \text{ df}, P < 10^{-20}$). For BRCA2 both ER and grade were highly significant predictors of mutation status, and the interaction of ER and grade was also quite significant ($\chi^2 = 28.3, 2 \text{ df}, P < 10^{-6}$). The addition of TN did not improve the model fit significantly ($P = 0.14$) when ER and grade were included in the model. We thus considered ER, grade, and TN status in deriving likelihood ratio estimates for BRCA-mutation status.

**ER and grade as predictors of mutation status**

The estimated likelihood ratios for predicting BRCA1 or BRCA2 mutation status defined by breast tumor ER-grade phenotype, adjusted for country by using stratified analysis, are shown in Table 2. Results based on pooled data unstratified for country, including cell counts, are shown in Additional file 1: Table S2. In general, the Mantel-Haenszel stratified LR estimates were quite similar to the pooled estimates, with stratified estimates most often closer to 1.0 (although not always). Significant between-country heterogeneity for the estimated likelihood ratios was most often observed with grade rather than ER or TN status. ER-positive cases were less likely to be carriers of a BRCA1 mutation, irrespective of grade. Conversely, ER-negative cases with high-grade tumors were more likely to be BRCA1 mutation carriers. Further, our analyses showed that ER-positive grade 3 tumors were modestly predictive of positive BRCA2 mutation status (Table 2). The association of BRCA2 mutation status with ER-positive high-grade tumors was not substantially different for women diagnosed at younger or older than age 50 years (LR $<50$ years = 1.77 (95% CI, 1.60 to 1.95), LR $\geq$50 years = 1.76 (95% CI, 1.49 to 2.08)). However, ER-negative grade 3 tumor status was modestly predictive of positive BRCA2 mutation status in women diagnosed at 50 years or older (LR, 1.54; 95% CI = 1.27 to 1.88).

It is well known that ER and grade status are correlated, with ER-negative tumors more likely to present with high grade. Consistent with this, relatively few cases appeared in any of the sample sets with ER-negative grade 1 tumors. However, we estimated LRs for ER alone and grade alone to allow inclusion of pathology data in models for predicting BRCA1 and BRCA2 mutation status, in instances in which information for only one of these variables is available (Table 2). For example, for a woman diagnosed with breast cancer at 50 years or older, the LR in favor of positive BRCA1 mutation status would be 3.5 if her tumor were known to be ER negative but grade status was unknown, and 2.4 if reported as grade 3 without information on ER status.

An acknowledged caveat to the inclusion of pathology data in multifactorial likelihood modeling is the underlying assumption that missense and in-frame deletions considered to be pathogenic mutations will exhibit the same tumor histopathological characteristics as do truncating mutations. The dataset in this study included 398 known pathogenic BRCA1 missense mutation carriers (mainly C61G), and 44 pathogenic BRCA2 missense mutation carriers with information on ER status or grade. Comparing the missense variants with the truncating set of mutations, we found no significant association of BRCA1 mutation type with ER status (OR = 0.9; 95% CI, 0.7 to 1.2; $P = 0.4$) or grade (OR = 1.15; 95% CI, 0.9 to 1.4; $P = 0.2$) or BRCA2 (OR = 2.7; CI, 0.9 to 7.6; $P = 0.07$ for ER; OR = 0.6 0.3 –to 1.2; $P = 0.14$ for grade), although power was quite limited for BRCA2.

**Triple-negative (TN) phenotype in BRCA1 and BRCA2 carriers**

Secondary country-stratified analysis of 2,249 BRCA1, 1,195 BRCA2 and 19,178 assumed mutation-negative breast cancer cases (Table 3) indicated that TN tumor status is highly predictive of BRCA1 mutation status for women diagnosed at younger than 50 years (LR = 3.73; 95% CI, 3.43 to 4.05) and at age 50 years or older (LR = 4.41; 95% CI 3.86 to 5.04), and results were little different for unstratified analysis (see Additional file 1: Table S3, also displaying cell counts).

Results also indicated that TN phenotype is modestly predictive of BRCA2 mutation status in cases diagnosed at age 50 years or older (LR, 1.79; 95% CI = 1.42 to 2.24). This observation is explained by the lower frequency of the TN phenotype in noncarriers (12.9% 50 years or older) versus BRCA2 mutation carriers (23.5% 50 years or older). Additional analysis considering grade and TN status combined (see Additional file 1: Table S4) did not show substantial improvement over LRs estimated for ER and grade combined (Table 2) or TN status (Table 3), although numbers in some cells were limited.

**Sensitivity analyses**

With respect to the possible consequences of contamination by missed mutation carriers in the BCAC sample set, we first estimated which BCAC-untested cases were more likely to be an undetected mutation carrier, and then re-estimated a subset of the LRs by using iterative sampling of the control dataset. Based on age-specific relative risks, we estimated that there could be at most 796 BRCA1 (1.7%) and 433 BRCA2 (0.9%) undetected carriers in the reference dataset of 47,565 BCAC cases. Based on age and crude ER, LR estimated from true non-carriers in BCAC, of 41,515 BCAC cases whose genetic status was unknown, 34,869 (84%) had posterior probabilities of being a true BRCA1/2-negative case greater than 0.95, with the minimum posterior probability being 0.89. Repeating this sampling process a total of
5 times, the number of BRCA1 carriers within the BCAC set ranged from 688 to 784, and the number of BRCA2 carriers ranged from 410 to 455 (total carriers, 1,114 to 1,194). Re-estimation of a subset of LRs indicated that the LRs assuming all BCAC cases do not carry a pathogenic BRCA1 or BRCA2 mutation is quite close to what we would expect, had all individuals been tested. For ER-negative Grade 3 cases diagnosed at younger than 50 years, the original LR for BRCA1 mutation status, assuming all BCAC cases were non-carriers, was 3.16, whereas the five replicates from iterative analysis ranged from 3.22 to 3.25. For TN tumor phenotype, the original LR for BRCA1 mutation status was 3.73, whereas the median of the five replicates was 3.76.

In additional sensitivity analyses, we recalculated unstratified LRs for ER and grade combined, restricting the analyses to the subset of 36,522 (33,260 BCAC, 3,252 CIMBA) breast cancer cases of European ancestry, of which 31,374 (28,364 BCAC, 3,010 CIMBA) were diagnosed within 5 years of interview, and 40,874 (36,414 BCAC, 4,460 CIMBA) were diagnosed after 1989. Results were similar to those from the overall analyses, with LR estimates consistently within the confidence intervals of the overall analyses.

**Discussion**

**Histopathological predictors of mutation status**

This study assessing histopathological predictors of BRCA1 and BRCA2 mutation status is based on the largest sample set reported to date, and so provides more precise estimates that account for age at diagnosis as a potential confounder. We also provide age-stratified LRs for ER alone and grade alone, which, although not as predictive as ER and grade combined, will facilitate inclusion of minimal pathology information in multifactorial modeling of individually rare variants.

Further, we provide, for the first time, LR estimates for TN status that can be applied when grade information is not recorded, with estimates associated with TN status comparable to those for ER-negative-grade 3 (for BRCA1) and ER-positive-grade 3 (for BRCA2). Altogether, these refined LRs will improve the clinical classification of BRCA1 and BRCA2 variants, particularly those identified in women with later age at diagnosis.

Our ER-grade analysis results for BRCA1 are consistent with results from analysis of raw data for a smaller dataset of 600 BRCA1 carriers aged younger than 60 years and 258 age-matched non-carriers from the Breast Cancer Linkage Consortium, which yielded LRs of 1.94 (95% CI = 1.05 to 3.56) and 2.95 (95% CI = 2.41 to 3.62) for ER-negative grade 2 and ER-negative grade 3 tumors, respectively [26,27]. However, the current study demonstrates that ER-negative grade 2 or 3 status is more predictive of positive BRCA1 status in women diagnosed at older than 50 years compared with younger than 50 (for example, for ER-negative-grade 3, LR ≥50 years is 4.13 (95% CI = 3.70 to 4.62) versus LR <50 years of 3.16 (95% CI = 2.96 to 3.37); \( P_{het} <0.0001 \). These observations reflect the fact that although the overall proportion of ER-negative high-grade tumors is lower for older onset (54.5%) than younger onset (67.1%) BRCA1 carriers (as previously reported [33,40]), the proportion of ER-negative high-grade tumors differs much more markedly for older-onset (12.8%) than younger-onset (20.8%) cases with no identified mutation in BRCA1 or BRCA2.

In addition, not reported in previous smaller studies [6,7,41], our results show that ER-positive grade 2 or 3 status is a stronger negative predictor of BRCA1 mutation status in women diagnosed before age 50 years compared with those diagnosed at age 50 years or older. These patterns reflect changes in the frequency of ER status and grade as a function of age in the non-carrier cases, rather than large changes in the frequency of these features in the carriers. Similarly, the findings for BRCA2 are consistent with those from a previous study of 157 BRCA2 mutation carriers and 314 mutation-negative familial breast cancer cases, which indicated that BRCA2-associated tumors were more likely to be ER-positive than were control tumors, when accounting for grade (OR, 2.09; 95% CI, 1.21 to 3.63; \( P =0.008 \) [13].

However, age-stratified analysis highlighted that ER-negative grade 3 tumor status modestly predicted positive BRCA2 mutation status in women diagnosed at age 50 years or older, indicating that grade is a more important factor than ER status in predicting BRCA2 tumors. We attempted to assess pathology difference by mutation type (missense versus truncating), an issue that has not previously been addressed rigorously because of the limited availability of pathology information for proven high-risk missense mutations. However, even in our very large dataset, the number of proven pathogenic missense mutations remained small, and it is apparent that future even larger studies will be needed to address this question.

The associations between BRCA1 mutation status and TN phenotype are consistent with those observed for ER-negative, high-grade tumors. They are also consistent with prior evidence that BRCA1 mutation carriers are enriched for the “basal” tumor phenotype that is highly concordant with TN status. A recent meta-analysis assessing the prevalence of BRCA1 mutations in TN versus non-TN breast cancer patients from largely high-risk breast cancer populations [42] estimated a risk of 5.65 (95% CI, 4.15 to 7.69) based on analysis of 236 BRCA1 mutation carriers and 2,297 non-carriers. In addition, these authors predicted that approximately two in nine women with TN breast cancer and additional high-risk features (early onset or family history) harbor a BRCA1 mutation [42]. TN status has not been obviously linked
to BRCA2 mutation status previously; however, a recent study of 43 deleterious BRCA1/2 mutation carriers identified from screening of 409 Chinese familial breast cancer cases reported that TN phenotype was more likely to be exhibited by both BRCA1 (P = 0.001, 69%, n = 16) and BRCA2 (P = 0.01, 46%, n = 27) carriers identified in their cohort, compared with non-carriers (23%; n = 366) [43]. In contrast, a similar study of 221 Korean familial breast cancer patients [44] identified 81 deleterious mutation carriers, and demonstrated increased TN phenotype for BRCA1 mutation carriers (P < 0.00001, 57%, n = 35), but not BRCA2 mutation carriers (P = 0.9, 13.9%, n = 36) compared with non-carriers (13%, n = 130). Neither of these studies presented their findings for cases stratified by diagnosis age 50 years or older.

Our study has shown that TN phenotype is modestly predictive of BRCA2 mutation status in cases diagnosed at 50 years or older, due to a lower TN frequency in non-carriers versus BRCA2 mutation carriers in this age group. Reassuringly, these TN frequency differences mirror the results seen for ER-negative grade 3 status in non-carriers and BRCA2 mutation carriers, an analysis based on a much larger sample set.

Possible impact of study limitations

We acknowledge several limitations of our study. Ideally, our reference group would have been drawn from the same source as the mutation carriers, as there may be differences between non-BRCA familial cases and unselected cases. However, in the subset of 30,233 BCAC cases that had data on family history, we did not see any significant differences between this group and the remainder of the sample in terms of the pattern of pathological features, nor with those who indicated no first- or second-degree relatives with breast cancer.

In our analyses, we are implicitly assuming that testing for BRCA1/2 mutations was independent of the histopathology features used for prediction of mutation status. Although recently some features with therapeutic implications, such as TN status, are being used as a criterion for testing in some centers, we believe that the vast majority of our CIMBA carriers were tested solely on the basis of their family history. This analysis assumes that mutation testing in CIMBA sample sets was not directed by tumor histology. Mutation status was not known for all BCAC samples. However, mutation testing of BCAC samples had been performed for many studies with selected design that might be expected to be enriched for BRCA1 and BRCA2 mutation carriers, and these known mutation carriers were excluded from analysis.

Further, our sensitivity analyses suggest that, at very most, 2.5% of BCAC cases might carry an undetected mutation, and also show that our results would not be substantially affected by this level of contamination of the reference group.

The various sensitivity analyses conducted for the ER-grade dataset provided no convincing evidence for obvious differences for the factors being assessed. We did not see any marked difference in LR estimates for analyses restricted to individuals of European ancestry, but the small numbers of cases from other ethnic/racial groups did not allow us to assess reliably tumor histopathological features for other ethnic groups, and so may not be generalizable to patients of non-European ancestry. Although it is possible that variation in pathology grading and IHC testing methods might occur between countries or over time, our investigations provided no evidence that such differences would meaningfully confound interpretation of the results, and thus should not limit the use of the information generated for multifactorial likelihood analysis of BRCA1 or BRCA2 variants across continents.

Use of revised LR estimates for future multifactorial likelihood analyses

This study has re-estimated the likelihood of BRCA1 or BRCA2 mutation status associated with breast tumor features commonly measured in the clinical setting, by analyzing much larger datasets than previously used for this purpose. Our findings provide measures of confidence in the individual LR estimates, and in particular, allow age at diagnosis to be incorporated into the pathology component of the multifactorial likelihood model. Figure 1 provides a flowchart indicating the proposed application of pathology-based LRs, dependent on what breast tumor pathology information is available for a variant carrier. As indicated, ER-grade LRs should be applied in preference to other pathology LR estimates, where both ER and grade information is available. The ER-grade LRs were derived from analysis of the largest sample sizes and thus have the greatest precision, and application of 12 strata provided by three grade categories refines both positive and negative prediction of mutation status. For example, a patient with a high-grade ER-negative tumor is three- to fourfold more likely to carry a BRCA1 mutation than not, whereas a patient with a low-grade ER-positive tumor is about 10 times more likely to be mutation-negative than mutation-positive. Given that grade and ER are almost universally used to assess prognosis and predict response to antiestrogen therapies, these features are generally readily available on standard pathology reports.

This study could not provide a comparison to existing LR estimates of BRCA1 mutation status based on ER-CK status, determined from analysis of 182 BRCA1 and 109 age-matched cases [6]. However, we caution that very large confidence limits exist around the previously estimated LRs for ER-CK characteristics, and recommend further
study of large carrier and reference sample sets to provide more-robust LR estimates for ER-CK phenotype in relation to mutation status.

It is important to note that the LRs estimated in this study were from analysis of sample sets that were, to our knowledge, unselected for tumor pathology status. Therefore, it will be necessary to consider potential for bias when individuals are screened for mutations on the basis of their tumor phenotype. This is expected to occur increasingly, now that BRCA1/2 mutation-prediction programs such as BOADICEA include pathology as a component [16], and given recent evidence supporting implementation of the National Comprehensive Cancer Network (NCCN) guidelines that recommend testing of all TN breast cancer patients aged 60 years or younger [45]. In this scenario, multifactorial likelihood analysis should exclude tumor-pathology information from individuals who had previously contributed to risk prediction used to prioritize families for mutation screening. However, pathology data generated subsequently from other variant carrier relatives can still provide independent information toward variant classification.

We are aware that, in the future, other tumor characteristics could provide useful information for variant classification. Array Comparative Genomic Hybridization (CGH) has been shown as an effective method to identify BRCA1-mutated breast cancers and sporadic cases with a BRCA1-like profile [46,47] for appropriate chemotherapeutics, and to distinguish BRCA2-mutated tumors from sporadic breast tumors [48]. If introduced widely as a routine test, this approach might be considered in the future as an alternative predictor in multifactorial modeling. Furthermore, the mutual exclusivity of BRCA1-germline mutations and BRCA1 promoter methylation in tumors with BRCA1-like CGH profile [49] suggests that BRCA1 promoter methylation tests would add value in distinguishing...
somatic from germline loss of BRCA1 function, as is established for clinical testing triage and variant classification relating to MLH1 mismatch repair cancer-predisposition gene [50]. Alternatively, genome-wide tumor-methylation profiles may prove of value to distinguish between individual with and without a germline BRCA1 mutation [51]. Further, additional stratification of currently used histological features may add value in prediction of mutation status. Options include PTEN loss of expression in addition to TN status as a marker of BRCA1 mutation status [11], or gene-expression arrays to identify BRCA2 mutation carriers among the subset of luminal B tumors [15].

Recent research has also shown the value of considering further stratification of breast cancer subtype in the prediction of BRCA1 mutation status. For example although ER-negative status clearly predicts BRCA1 mutation status, even ER-positive BRCA1-related breast cancers are more likely to be grade 3, CK14+, and show high mitotic rate compared with ER-positive sporadic cancers [52]. In addition, possibilities exist to extend histopathological analyses to tumors other than female breast cancer. The combination of modified Nottingham grade 3 serous or undifferentiated histology, prominent intraepithelial lymphocytes, marked nuclear atypia with giant nuclei, and high mitotic index has recently been reported to be a significant predictor of BRCA1 mutation status in women with epithelial ovarian cancer [53]. Further, breast tumors of male BRCA2 mutation carriers are more likely to present as high-grade, PR-negative, and relatively high rates of HER2-positivity with a micropapillary component to histology have been reported [54,55]. Investigation of these features in larger sample sizes should be considered in the future.

Although this article has focused on the utility of histopathologic features of breast cancers in the context of the classification of variants in the BRCA1 and BRCA2 genes, these results should also be useful in a range of other applications. The information provided in the main tables can be used to estimate sensitivities and specificities of histopathological predictors by broad age-group (for example, triple-negative tumor status has sensitivity of 0.67 and specificity of 0.82 for detection of BRCA1 mutation status in women diagnosed at younger than age 50 years, whereas the sensitivity is 0.57 and the specificity 0.87 for women diagnosed at age 50 or older. As such, these results, in conjunction with other predictors of mutation status, could be useful to guide systematic genetic testing of germline DNA from patients to determine the appropriateness of the use of PARP inhibitors in therapy. The results arising from this study are also likely to inform future development of parallel models, which estimate the probability of an individual carrying a BRCA1 or BRCA2 mutation, to determine eligibility and/or priority for genetic testing (in particular, the BOADICEA model, which has recently been updated to include additional histopathologic characteristics from large data resources [56]).

**Conclusions**
The results from this large-scale analysis refine likelihood ratio estimates for predicting BRCA1 and BRCA2 mutation status by using commonly measured histopathological features. We demonstrate the importance of considering age at diagnosis for analyses, and show that grade is more informative than ER status for BRCA2 mutation-carrier prediction. The estimates will improve BRCA1 and BRCA2 variant classification by using multifactorial likelihood analysis, and inform patient mutation testing and clinical management.

**Additional file**

| Additional file 1: Table S1. CIMBA and BCAC sample sets included in analysis. | Table S2. Unstratified estimated likelihood ratios (LRs) for predicting BRCA1 or BRCA2 mutation status defined by breast tumor ER-grade phenotype. Table S3. Unstratified estimated LRs for predicting BRCA1 or BRCA2 mutation status defined by breast tumor triple-negative phenotype. Table S4. Unstratified estimated LRs for predicting BRCA1 or BRCA2 mutation status defined by breast tumor TN-grade phenotype. * |

**Abbreviations**

BCAC: Breast Cancer Association Consortium; CGH: Array Comparative Genomic Hybridization; CIMBA: Consortium of Investigators of Modifiers of BRCA1/2; CK14: cytokeratin 14; CK17: cytokeratin 17; COS5/6: cytokeratin 5/6; EGRF: epidermal growth factor receptor; ENIGMA: Evidence-based Network for the Interpretation of Germline Mutant Alleles; ER: estrogen receptor; HER2: Human epidermal growth factor receptor 2; IHC: immunohistochemical; LR: likelihood ratio; NCCN: National Comprehensive Cancer Network; PR: progesterone receptor; PTEN: phosphatase and tensin homolog; TN: triple negative.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ABS, FJC, and DEG conceived and designed the study. ABS and MTP coordinated data collation for analysis, and DEG performed the statistical analysis. ABS and DEG drafted the manuscript. ACA, LMcG, DB, and SH coordinated the cleaning of pathology data, risk factor data, and mutation classification for CIMBA, overseen by GC-T. MKS, MB, and QW coordinated the collation and cleaning of pathology and risk-factor data for BCAC, overseen by DFE. FJC, RK5, BW, KR, EH, CE, A Meindl, ND, NA, HP, DN, C Sutter, SW-G, DS, SP-A, KK, RV-M, SDE, DF, RP, E Perkins, DGE, LJ, RE, JA, RD, TC, GS, S Manoukian, B Bonanni, F Mariette, SF, AV, BP, LP, LV, RB, KLN, SMED, KDO, AI, NL, MT, UBJ, JR, AB, IRL, A Milon, TV-OH, TC, SLN, AET, HHN, MM, J Garber, AKG, AO, RE, MB, MBB, TVO, BWM, TPS, P Hillelmanns, CAH, BEH, MS, LLM, B Busseinici, FM, MARNE, HS, RF, HA-C, AZ, MUH, JMC, JWWM, MMT-L, HB, AKD, VA, C Stegmaier, RW, KP, AU-V, MG, AL, S Margolin, VJ, MR, RR-M, AGN, JIA, PJ, JB, AM, VM, V-K, JM, PP, DZ, MB, FC, PR, SH, and GC-T contributed to baseline study design and recruitment of subjects included in the analysis, and provided access to genetic, epidemiologic, and pathology data from these characterized cohorts. All authors read and approved the final manuscript.
Acknowledgements

Amanda Spurdie is supported by an NHMRC Senior Research Fellowship, and aspects of this research were funded by Australian NHMRC Project grant ID 1010719. This work was supported in part by NIH grants CA128978 and CA116167, an NIH specialized program of research excellence in breast cancer to the Mayo Clinic (P50 CA116201), and the Breast Cancer Research Foundation. CIMBA data management was supported by Cancer Research-UK grant C12292/A11174 and C1287/A10118. ACA is a Cancer Research-UK Senior Cancer Research Fellow. BCAC data management was funded by Cancer Research UK (C1287/A10118 and C1287/A12014) and by the European Community’s Seventh Framework Programme under grant agreement 223175 (HEALTH-F2-2009-223175).

Study-specific Acknowledgements

ABCs was supported by Dutch Cancer Society grants NKI 2007-3839; 2009 4363. ABCFS thanks Maggie Angelakos, Judi Maskiell, Gillian Dite, and Helen Tsimiklis. The Australian Breast Cancer Tissue Bank is generously supported by the National Breast Cancer Foundation, the Australian Foundation for Medical Research, the Australian Cancer Research Foundation, the Breast Cancer Family Registry, the Cancer Institute NSW, and the National Breast Cancer Foundation. The work of the BBCS was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Research Network (NCRN). The work of the Breast Cancer Family Registry (BCFR) centers (BCFR-AU (ABCFS), BCFR-NC, BCFR-NY, BCFR-ON (OFBCR), BCFR-PA ( FCCC, and BCFR-UT was supported by grant U11 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the Breast Cancer Family Registry. BCFR-ON (OFBCR) work was additionally supported by the Canadian Institutes of Health Research “CIHR Team in Familial Risks of Breast Cancer” program. BIOMC is supported by the Breast Cancer Research Foundation. For BRCOH, data were collected under NIH RO1 CA74415. SLN is holder of the Morris and Horowitz Families Endowed Professorship. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society, and the German Cancer Research Center (DKFZ). CBCS thanks Anne-Marie Gerdes and Bent Ejlersen for clinical data. The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev Hospital. CGPS thanks staff and participants of the Copenhagen General Population Study. For the excellent technical assistance, thanks to Dorte Ulldahl Andersen, Maria Birta Arnadottir, Anne Bank, and Dorte Kjeldgaard Hansen. The Danish Breast Cancer Group (DBCG) is acknowledged for the tumor information. The work of CNIO was partially supported by Spanish Association against Cancer (AECOC08). RTCC 06/2002/1060, FIS/P09/1120, Mutua Madrileña Foundation (FMMA) and SAF2010-20493. MBCSG and CONSIT TEAM is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1,000 share of their tax payment according to Italian laws in support of the Fondazione IRCCS Instituto Nazionale Tumori to SM and of the IRCCS AOU San Martino IST to LV and from FiorGen Foundation for Pharmacogenomics to LP. MBCSG and CONSIT TEAM thank Bernard Peisel of the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; Laura Ottini and Giuseppe Giannini of the Sapienza University, Rome, Italy; Antonella Savarese and Aline Martayan of the Istituto Nazionale Tumori Regina Elena, Rome, Italy; Maria Grazia Tibiletti and Daniela Furlan of the Ospedale di Circolo, Università dell’Insubria, Varese, Italy; Stefania Tommasi of the Istituto Nazionale Tumori “Giovanni Paolo II, Bari”, Italy, and Loris Bernard and the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy. The University of Westminster curates the DietCompLy database created by and funded by Against Breast Cancer Registered Charity No. 1121258. DKFZ are grateful to all the patients for their participation in this study. The HEBonjour (ld.rangle@inlknl.nl) study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the NWO grant 91010924, the Pink Ribbon grant 110005 and the BBMRI grant CP46/NWO. The HEREDITARY Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating center: Netherlands Cancer Institute, Amsterdam, The Netherlands. EMBRACE (dfe20@medischl.cam.ac.uk) is supported by Cancer Research UK Grants C1287/A10118 and C1287/A11990. D. Gareth Evans and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles and Elizabeth Bankoff are supported by Cancer Research UK Grant C5047/A8385, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. ESTHER was supported in part by the Baden-Württemberg State Ministry of Science, Research and Arts, and by the German Federal Ministry of Education and Research. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). We thank all the individuals who took part in this study and all the researchers, clinicians, technicians, and administrative staff who have enabled this work to be carried out. The FCCC thanks Ms. JoEllen Weaver, and Dr. Betsy Bove for their technical support. The authors acknowledge support from The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. AKG was funded by SU10CA113916, R01CA140323, and by the Challengers Distinguished Chair in Biomedical Sciences Professorship. GC-HBOC was kindly supported by the German Cancer Aid to R. K. Schmutzer (grant 109076). We are very thankful to all family members who participated in this study. The GENICA (hiltrud.brauch@ikp-stuttgart.de) was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01K0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus Bonn, Germany. The GENICA network (Dr. Margareta Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Germany; HB, WIng-Yee Lo, Christina Justenhoven), Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany (YKD, Christian Baisch), Institute of Pathology, University of Bonn, Germany (Hans-Peter Fischer), Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Germany [Ute Hamann], Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Germany [TB, Beate Pesch, Sylvia Rabstein, Anne Lotz], Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany [Volker Harth]. Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany. University of Tübingen, Geschwister-Scholl-Platz, 72074 Tübingen, Germany. Dr. Margareta Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstraße 112, 70376 Stuttgart, Germany. Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany. Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Institute of Pathology, Medical Faculty of the University of Bonn, Sigmund-Freud-Stra 25, Haus 372, 53127 Bonn, Germany. Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Johanniterstrasse 3, 53113 Bonn, Germany. The GESEVC was supported by the Deutsche Krebshilfe e. V. (70492), and genotyping in part by the state of Baden-Württemberg through the Medical Faculty of the University of Ulm (P.685). The HABCs study was supported by an intramural grant from Hannover Medical School. HCSC was supported by grant RD12/0036/006. Instituto de Salud Carlos III (FEDER), Spanish Ministry of Science. The HBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation. HBCS thanks Kirsiimari Aaltonen, Karl von Smitten, and Irja Erkkilä. IOVHBCS was supported by Ministero dell’Istruzione, dell’Università e della Ricerca and Ministero della salute.
Financial support for KARBARC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm City Council and Karolinska Institutet, and from the Stockholm Cancer Foundation and the Swedish Cancer Society. The MBKC was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants; Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland, and by the strategic funding of the University of Eastern Finland. KConFab (heather.thorne@petermac.org) is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC), and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. GCT is an NHMRC Senior Principal Research Fellow. RB was a Cancer Institute NSW Clinical Research Fellow. We thank Heather Thorne, Eveline Niedermayr, all the KConFab research nurses and staff, the heads and staff of the Family Cancer Clinics. Peter MacCallum Cancer Centre, 7 St Andrews Pl, East Melbourne VIC 3002, Australia.

The ORIGO study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I], the Hamburg Cancer Society, the German Cancer Research Center, and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MARIE thanks Alina Vrieling, Katharina Buc, Muhabbet Celik, Ursula Elber, and Sabine Behrens. MAYO is supported by NIH grant CA128978, an NO Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA16201), a U. S. Department of Defense Ovarian Cancer Idea awary (W81XWH-10-1-0341) and a grant from the Breast Cancer Research Foundation. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and from the Italian citizens who allocated the 5/1,000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects ‘5 x 1000’). The MCBCS was supported by the NIH grant CA128979 and a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsou and We Fong Chao Foundation. MCCS cohort recruitment was funded by ViHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 20057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. The MEC was support by NIH grants CA63464, CA54281, CA098758, and CA132839. MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. OBSC thanks Meen Otsuka, Kari Mononen, Jukka Mollanen, Salla Kaupilia. OBSC was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland Centre of Excellence grant 251314, the Sigrid Juselius Foundation, the University of Oulu, and the Oulu University Hospital Research Fund. OFSCR was supported by grant UM1 CA164020 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.

The ORIGO study was supported by the Dutch Cancer Society (RUL 1997- 1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16).

OSU CCG thanks Leigha Senter, Kevin Sweet, Caroline Craven, and Michelle O’Connor, who were instrumental in accrual of study participants, ascertainment of medical records, and database management. The ONCO-BCS was supported by the Genome Spain Foundation, the Red Tematica de Investigacion Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigacion Sanitario (PI11/00923 and PI011120). The Human Genotyping-CEGEN Unit (CNIO) is supported by the Instituto de Salud Carlos III. Thanks to Guillermo Pita, Charo Alonso, Daniel Herrero, Nuria Alvarez, Pilar Zamora, Primitiva Menendez, and the Human Genotyping-CEGEN Unit (CNIO). The PRBC was supported by the Intramural Research Programs of the Division of Cancer Epidemiology and Genetics and Center for Cancer Research of the National Cancer Institute.

The pKARMA study was supported by Märit and Hans Rausings Initiative Against Breast Cancer. POSH was supported by Cancer Research UK (grant ref A7572, A11699, C22524) and Breast Cancer Campaign 2005NOV53. RBCS thanks Petra Bos, Jannet Blom, Ellen Crepin, Anja Nieuwaalt, Annette Heemskerk, and the Erasmus MC Family Cancer Clinic. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institutes of Health (NIH), and the Susan G. Komen Breast Cancer Foundation. SBCS thanks Sue Higham, Helen Cramp, Ian Brock, Dan Connelly, and Sabapathy Babasubramanian. The SBCS was supported by Yorkshire Cancer Research, S295, S299, S305PA. SEARCH was supported by grants CRUK A490/A11021, C490/A16561. SEARCH thanks Marie Mack and Mitul Shah.

SKDKFR25 are grateful to all the patients for their participation. We thank the physicians, other hospital staff and research assistants who contributed to the patient recruitment, data collection, and sample preparation.

SIBRA collaborators are instruments of the Swedish Cancer Society. The IHCC and SZBCS studies were supported by Grant P82, KBN, 122/P005/2004. The UCIBCS component of this research was supported by the NIH (CA58860, CA92044) and the Leon V Smith Foundation (LYS53420). UPENN is funded by National Institutes of Health (NIH) R01-CA102776 and R01-CA03885; Breast Cancer Research Foundation, Susan G. Komen Foundation for the Cure, Basser Research Center for BRCA. The Women’s Cancer Program (WCP) at the Samuel Oschin Comprehensive Cancer Institute is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-C0UN).

Author details

1Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute. 300 Herston Road, Brisbane, QLD 4006, Australia.
2Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
3Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
4Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
5Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.
6Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Härtestrasse 16-18, 04107 Leipzig, Germany.
7Division of Gynaecology and Obstetrics, Technische Universität München, Immaninger Straße 22, 81675 Munich, Germany.
8Department of Gynaecology and Obstetrics, Ludwig-Maximilians-Universität, Maistrasse 11, 80337 Munich, Germany.
9Department of Gynaecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
10Institute of Human Genetics, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
11University Medical Center Schleswig-Holstein, Kiel, Germany.
12Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
13Institute of Human Genetics, University Hospital Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.
14Department of Gynaecology and Obstetrics, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
15Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
16Institute of Human Genetics, University of Münster, Münster, Germany.
17Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
18Institute of Human Genetics, Campus Virchow Klinikum, Charité Berlin, Germany.
19Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
20Clinical Genetics, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.
21Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.
22Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK.
23Department of Clinical Genetics, Southern General Hospital, 1345 Govan Road, Glasgow G51 4TF, UK.
24West Midlands Regional Genetics Service, Birmingham Women’s Hospital Healthcare NHS Trust, Edgbaston, Birmingham, UK.
25Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Via Giacomo Venezian, 1, 20133
Milan, Italy. 26Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Via Giuseppe Raimondi, 435, 20141 Milan, Italy. 27FOM, Fondazione Istituto Ricerca Molare, Via Adalberto, 16, 20139 Milan, Italy. 28Cogenetech Cancer Genetic Test Laboratory, Via Adalberto, 16, 20139 Milan, Italy. 29Division of Experimental Oncology 1, CRO Aviano National Cancer Institute, Via Franco Gallinii 2, 33081 Aviano, Pordenone, Italy.
30Department of Medical Sciences, University of Turin, Via Santena 19, 10126 Turin, Italy. 31AOU Città della Salute e della Scienza, corso Bramante 88 10126 Turin, Italy. 32Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Viale Pieraccini 50 50139 Florence, Italy. 33Unit of Hereditary cancer, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, largo Rosanna Benzi 10 16132 Genoa, Italy. 34Western Sydney and Nepean Blue Mountains Local Health Districts, Westmead Millennium Institute for Medical Research, University of Sydney, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia. 35Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. 36Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 417 East 68th Street, New York, NY 10021, USA. 37Department of Genetic and Genome Services, Case Western Reserve University Medical School, 2109 Adelbert Rd, Cleveland, OH 44106-4955, USA. 38Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. 39Molecular Oncology Laboratory, Hospital Clinico San Carlos, IDiSC, Martin Lagos s/n, Madrid, Spain. 40Beckman Research Institute of City of Hope, 1500 East Duarte Rd, Duarte, CA 91010, USA. 41Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, 998 Biomedical Research Tower, Columbus, OH, USA. 42Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 8, Helsinki FI-00029, HUS, Finland. 43Department of Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata 64, Padua, Italy. 44Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA. 45Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, 4019 Wahl Hall East, MS 3040 Kansas, KS, USA. 46Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, 28029 Madrid, Spain. 47Biomedical Network on Rare Diseases (OBEBER), Madrid, Spain. 48Department of Pathology, University of Utah Health Sciences Center, 50 N Medical Dr, Salt Lake City, UT 84132, USA. 49Department of Epidemiology, Columbia University, New York, NY, USA. 50Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290 W, Los Angeles, CA, USA. 51Cancer Genetics Laboratory, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. 52Institute of Medical Genetics, Austrian Cancer Research Center, 7032 Kals am Grossglockner, Carinthia, Austria.
53Institute of Molecular Genetics and Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 580 69120 Heidelberg, Germany. 54Department of Basic Sciences, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC) 7A, Block RS, Johar, Pakistan. 55331 Brookline Avenue, Boston, MA 02215, USA. 56Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. 57Department of Oncology, University of Cambridge, Cambridge, UK. 58Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, Stockholm SE-17177, Sweden. 59Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands. 60David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA. 61Department of Gynecology and Obstetrics, University Breast Center Fränkonia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Universitätsstrasse 21-23, 91054 Erlangen, Germany. 62Institute of Human Genetics, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Schlossplatz 4, 91054 Erlangen, Germany. 63Jonsson Comprehensive Cancer Center, University of California-Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90024, USA. 64Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 74, 2730 Herlev, Denmark. 65Department of Clinical Biochemistry, Herlev University Hospital, Copenhagen University Hospital, Herlev Ringvej 74, 2730 Herlev, Denmark. 66Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. 67Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 74, 2730 Herlev, Denmark. 68Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. 69Department of Cancer Epidemiology/Clinical Cancer Registry and Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany. 70Department of Clinical Genetics, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 8, Helsinki FI-0029, HUS, Finland. 71Department of Pathology, Helsinki University Central Hospital, Haartmaninkatu 8, Helsinki FI-0029, HUS, Finland. 72Department of Cancer Epidemiology and Genetics, National Cancer Institute, 6969 Medical Center Drive, Rockville, MD 20850, USA. 73Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland. 74Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 75Cancer Prevention Institute of California, 2201 Walnut Avenue #300, Fremont, CA 94538, USA. 76Department of Health Research and Policy, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA 94305, USA. 77Institute of Human Genetics, Pontificia Universidad Javeriana, Carrera 7, Bogotá, CO 11001000, Colombia. 78Frauenklinik der Städtischen Krankenanstalten Berlin, Charité Universitätsmedizin, Campus Spandau, Martin-Luther-King-Strasse 9, 13125 Berlin, Germany. 79Institute of Pathology, Städtisches Klinikum Karlsruhe, Moltkestrasse 90, 76133 Karlsruhe, Germany. 80Department of Human Genetics & Department of Pathology, Leiden University Medical Center, Eindhovenweg 20, 2333, ZC Leiden, Netherlands. 81Department of Surgical Oncology, Leiden University Medical Center, Eindhovenweg 20, 2333 ZL Leiden, Netherlands. 82Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Centre, Groene Hildijkstraat 301, 3075 EA Rotterdam, Netherlands. 83Department of Clinical Genetics, Leiden University Medical Center, Eindhovenweg 20, 2333 ZC Leiden, Netherlands. 84Faculty of Medicine, University of Southampton, University Road, Southampton SO17 1BJ, England. 85Queen Mary University London, Mile End Road, London E1 4NS, England. 86Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 87Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK. 88Department of Molecular and Applied Biosciences, Faculty of Science and Technology, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK. 89Department of Pathology & Molecular Medicine, Juravinski Hospital, Concession St, Hamilton, Ontario LBV 1C3, Canada. 90Cancer Centre, McMaster University, Hamilton, ON LBV 1C4, Canada. 91Ontario Cancer Genetics Network, Lunenburg-Tanenbaum Research Institute of Mount Sinai Hospital, 600 University Avenue, Toronto, ON MSG 1X5, Canada. 92Cancer Epidemiology Centre, Cancer Council Victoria, 615 St Kilda Rd, Melbourne, Victoria 3004, Australia. 93Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, The University of Melbourne, Level 1, 723 Swanston Street, Melbourne, Victoria 3010, Australia. 94Anatomical Pathology, The Alfred Hospital, 55 Commercial Rd, Melbourne, Victoria 3004, Australia. 95Australian Breast Cancer Tissue Bank, Westmead Millennium Institute, University of Sydney, Darcy Rd, Sydney NSW 2145, Australia. 96Westmead Institute for Cancer Research, University of Sydney, Darcy Road, Sydney NSW 2145, Australia. 97Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, University Drive, Callaghan NSW 2305, Australia. 98Division of Genetics, Hunter Area Pathology Service, John Hunter Hospital, Lookout Road, Loomis Heights, Newcastle NSW 2305, Australia. 99University of Tübingen, Geschwister-Scholl-Platz, 72074 Tübingen, Germany. 100Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstraße 112, 70576 Stuttgart, Germany. 101Institute for Prevention and Cancer
24. de la Cruz J, Andre F, Harrell RK, Bassett JR, Arun B, Matheiu MC, et al. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. Hum Pathol. 2012;43:1932–40.

25. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004;75:535–44.

26. Spurdle AB, Lakhani SR, Healey S, Parry S, Da Silva LM, Brinkworth R, et al. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis—a report from the IConFab Investigators. J Clin Oncol. 2008;26:1657–63.

27. Chenevix-Trench G, Healey S, Lakhani SR, Wang P, Cummings M, Brinkworth R, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006;66:2019–27.

28. Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol. 2008;26:5939–49.

29. Sweet K, Senter L, Pilarski R, Wei L, Toland AE. Characterization of BRCA1 ring finger variants of uncertain significance. Breast Canc Res Treat. 2010;119:727–37.

30. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, et al. ENIGMA—evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012;35:2–7.

31. The Consortium of Investigators of Modifiers of BRCA1 and BRCA2. [http://ccge.medschl.cam.ac.uk/consortia/cimba/]

32. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 2007;9:104.

33. Mavaddat N, Barrodale D, Andrilis I, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–47.

34. Breast Cancer Association Consortium. [http://ccge.medschl.cam.ac.uk/consortia/bcac/]

35. Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer results from the Breast Cancer Association Consortium. J Natl Cancer Inst. 2006;98:1382–96.

36. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20:3289–303.

37. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. Brookline, MA: Epidemiology Resources Inc.; 1982.

38. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41:55–68.

39. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Breast Cancer AC. [http://ccge.medschl.cam.ac.uk/consortia/bcac/]

40. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of B, Breast Cancer and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients. J Natl Cancer Inst. 2014;106:1133–41.

41. Vaziri SA, Krumrey LM, Elston P, Budd GT, Darlington G, Myles J, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001;7:1937–45.

42. Turi NM, Villani G, Onig K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet. 2011;80:43–8.

43. Zhang J, Pei R, Pang Z, Qiu Yang T, Li J, Wang T, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Breast Canc Res Treat. 2012;132:421–8.

44. Seong MW, Kim KH, Chung H, Kang E, Lee JW, Park SK, et al. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients. Breast Canc Res Treat. 2014;146:63–9.

45. Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707–14.

46. Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AMJ, Imholz AL, et al. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCaness. Breast Cancer Res. 2011;13:R107.

47. Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, et al. Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. Breast Cancer Res Treat. 2013;139:317–27.

48. Joosse SA, Brandwijk KL, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, et al. Prediction of BRCA2-association in hereditary breast cancers using array-CGH. Breast Cancer Res Treat. 2012;132:579–89.

49. Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, et al. Triple-negative breast cancer: BRCaness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer. 2013;108:2172–7.

50. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRF1 mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012;49:151–7.

51. Flanagan JM, Cociarini S, Waddell N, Johnstone CN, Marsh A, Henderson S, et al. Genetic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer. 2012;12:510.

52. Ptacek TA, Oonk A, van der Kolk LE, Hogervorst FB, Healey S, Bonshoff FC, Chenevix-Trench G. DNA methylation of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet. 2010;86:420–33.

53. Kaplan JS, Schnitt SJ, Collins LC, Wang Y, Garber JE, Montgomery K, et al. Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA mutation carriers. Am J Surg Pathol. 2012;36:1483–8.

54. Fujiiwa A, McGuire VA, Felberg A, Sieh W, Whittimore AS, Longacre TA. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype. Am J Surg Pathol. 2012;36:1170–7.

55. Deb S, Jene N, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer. 2012;12:510.

56. Joosse SA, Brandwijk KL, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, et al. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype. Am J Surg Pathol. 2012;36:1170–7.

57. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010;12:R12.

58. Vaziri SA, Krumrey LM, Elston P, Budd GT, Darlington G, Myles J, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age of diagnosis. Clin Cancer Res. 2001;7:1937–45.

59. Turi NM, Villani G, Onig K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet. 2011;80:43–8.

60. Zhang J, Pei R, Pang Z, Qiu Yang T, Li J, Wang T, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Breast Canc Res Treat. 2012;132:421–8.

61. Seong MW, Kim KH, Chung H, Kang E, Lee JW, Park SK, et al. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients. Breast Canc Res Treat. 2014;146:63–9.

62. Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707–14.